You are here

Anticoagulant or thrombolytic therapy

Document
Last amended 
4 June 2015

Macular degeneration - Anticoagulant or thrombolytic therapy Factor

RMA definition

The RMA has defined anticoagulant therapy as therapeutic administration of a pharmacological agent which suppresses, delays or nullifies blood coagulation, (such as heparin, warfarin or dicumarol), but excludes antiplatelet therapy such as aspirin, clopidogrel, ticlopidine or monoclonal antibodies and recombinant and chemically synthesised peptides that block platelet adhesion or aggregation.

Brand names for anticoagulants

Brand names for these drugs include Calcihep, Calciparine, Coumadin, Dindevan, Marevan, Orgaran and Uniparin-CA. Refer to a MIMS publication or seek medical advice if you are unsure whether or not a particular medication is covered by the RMA definition.

Use of anticoagulants

Anticoagulant therapy may be used to treat conditions such as thrombophlebitis, venous thrombosis, coronary thrombosis, pulmonary embolism and occlusive vascular disease. It may also be used prophylactically to prevent such conditions and in the period following surgery, if the patient is at risk of developing thrombo-embolism. This form of treatment, however, carries with it a risk of haemorrhage in almost any tissue or organ of the body.

Establishing a history of anticoagulant use

A history of anticoagulant therapy should be documented in the evidence. However, if doctors' notes and hospitals' records cannot be obtained, a statement that anticoagulant therapy was given at a particular time will generally be accepted, unless there is contradictory evidence. Seek medical advice if it is unclear whether the claimed anticoagulant therapy is medically feasible.

Last reviewed for CCPS 27 April 2010

Preliminary questions [41147]

41179 there is some evidence that anticoagulant or thrombolytic therapy may be a factor in the development or worsening of the condition under consideration.

22645 the veteran's condition under consideration is late age-related macular degeneration.

41180 the veteran has had anticoagulant or thrombolytic therapy at some time.

41188 the veteran had anticoagulant or thrombolytic therapy for treatment of an illness or injury which is identifiable.

41181  the veteran has established the causal connection between anticoagulant or thrombolytic therapy and VEA service for macular degeneration.

41189 for treatment of the identified illness or injury, the veteran had anticoagulant or thrombolytic therapy within the one week before the clinical onset of the condition under consideration.

41182   the veteran has established the causal connection between anticoagulant or thrombolytic therapy and VEA service for the clinical onset of macular degeneration.

41184  the veteran has established the causal connection between anticoagulant or thrombolytic therapy and operational service for the clinical onset of macular degeneration.

or

41185  the veteran has established the causal connection between anticoagulant or thrombolytic therapy and eligible service for the clinical onset of macular degeneration.

or

7334     the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335     the condition under consideration permanently worsened.

41190 for treatment of the identified illness or injury, the veteran had anticoagulant or thrombolytic therapy within the one week before the clinical worsening of the condition under consideration.

41183   the veteran has established the causal connection between anticoagulant or thrombolytic therapy and VEA service for the clinical worsening of macular degeneration.

41186  the veteran has established the causal connection between anticoagulant or thrombolytic therapy and operational service for the clinical worsening of macular degeneration.

or

41187  the veteran has established the causal connection between anticoagulant or thrombolytic therapy and eligible service for the clinical worsening of macular degeneration.

Clinical onset and operational service [41184]

41191  the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related to operational service.

Clinical onset and eligible service [41185]

41192  the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related to eligible service.

Clinical worsening and operational service [41186]

41191  the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related to operational service.

41193 the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related.

Clinical worsening and eligible service [41187]

41192  the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related to eligible service.

41194 the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, for which the veteran had anticoagulant or thrombolytic therapy, is causally related.